Thank you National Cancer Institute for highlighting #Keynote546 , 1st PD1 inh trial with an OS benefit in #kidneycancer and other solid cancers. I wish we can have a more 'personalized' approach to therapy. Hope this will come soon enough!
cancer.gov/news-events/ca…
Happy Birthday to a nice husband person, 44 years young today 🥳🎂🎁. Life after his brief encounter with #kidneycancer #nephrectomy rolls on, with every birthday a bonus. Enduring gratitude for early diagnosis (incidental finding) and swift treatment 💙 #NHS Whittington Health NHS Trust & #UCLH
🔘 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer
#kidneyCancer #Immunotherapy National Cancer Institute Toni Choueiri, MD
cancer.gov/news-events/ca…
Watch Tom McClintock compare #PreExistingConditions to bad drivers who should be penalized under their auto insurance.
Well, Congressman, I just happen to be an EXCELLENT driver with #chronicillness who survived #kidneycancer and lives w/ #Lupus 🤔
Ab#4513 ASCO #ASCO24 👉tinyurl.com/4e9raesc👉Ph1 study of DFF332, a novel oral HIF2α inhibitor, in pts w/ aRCC #kidneycancer 👉promising safety profile & no grade 4 TRAEs or hypoxia reported👇Congrats Sumanta K. Pal, MD, FASCO Laurence Albiges for the oral abst OncoAlert UroToday.com Kidney Cancer
Ab#4508 ASCO #ASCO24 by Robert Motzer MD👉 tinyurl.com/yhk9457r 👉Final OS from JAVELIN Renal 101 ph3 trial #kidneycancer 👉 After ≥68 mos f-u, no OS benefit w/ avelumab/axitinib 👉making this regimen less optimal than other combinations👇 Toni Choueiri, MD OncoAlert UroToday.com
📣 CANCER CURRENTS: Dr. Mark Ball, an attending surgeon in our Urologic Oncology Branch, weighed in on results from a #ClinicalTrial that show survival improvement for #KidneyCancer patients treated with Pembrolizumab.
➡️ cancer.gov/news-events/ca…
📢Thrilled to share our lab's latest work where we found that #heritable & #spatial #immunogenic #traits predict efficacy of #immunotherapy responses in #kidneycancer #patients ! Nature Medicine
1/10🧵
OncoAlert OncoDaily MediMix OncLive.com
📑Read here: nature.com/articles/s4159…
📺 Catch Dan Joyce's (@VUMCDiscoveries) discussion with Sarah P. Psutka MD MS (@fredhutch) at #AUA24 on updates in #KidneyCancer research and how the treatment paradigm is changing as a result of #KEYNOTE564 .
🎥 Watch Now: buff.ly/4aavQRy
Couldn’t find my Kevin Owens shirt 😫 but after a 2 weeks pause back at it again! Cycle 2 Round 1 #kidneycancer #JustKeepFighting
#CCRNews : Congratulations to Dr. Ramaprasad Srinivasan for being appointed as a CCR Deputy Director! 👏 Dr. Srinivasan's commitments to developing targeted treatments for #KidneyCancer and increasing diversity in our #ClinicalTrials are greatly admired.
👉 #Spatial #proteomics emphasized #macrophage & #exhausted CD8+T cells #hub in #immunotherapy responsive #kidneycancer patients with #neoantigen -specific #HLA !
👉Here, #preexhausted CD8+T cells established dense #interactions with #proinflammatory #macrophage s & #Cancers !
6/10🧵
🌟 In episode 319 of the Uromigos (@brian_rini, Tom Powles), silke gillessen provides a preview of #ASCO24 , including presentations to look out for in the #prostate , #bladder , and #KidneyCancer fields.
👂 Listen Here: buff.ly/3KhsySh
Duke’s 1st Kidney cancer and microbiome symposium - Shahla Bari
Sumanta K. Pal, MD, FASCO William Y. Kim Jose Conejo-Garcia
Dan George Andrew Armstrong Jen-Tsan Ashley Chi
DCI Center for Prostate & Urologic Cancers Duke Microbiome Center
oncodaily.com/68113.html
#Cancer #KidneyCancer #OncoDaily #Oncology #Cancer Awareness
Three years of connection, support, and shared journeys! Patient Perspectives, our group dedicated to #kidneycancer patients and survivors, continues to shine as we mark its third anniversary. Here's to countless more moments of empowerment ahead!
Renal Cell Carcinoma in Adults: What patients should know about
National Cancer Institute American Cancer Society ASCO Memorial Sloan Kettering Cancer Center National Kidney Foundation Am Fam Physician Nebraska Hematology-Oncology The Lancet Oncology Scientific Reports
oncodaily.com/61382.html
#Cancer #KidneyCancer #RCC #PatientEducation #OncoDaily #Oncology
⚡️ On Nature Medicine - A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma
#KidneyCancer #Immunotherapy OncoAlert OncLive.com
nature.com/articles/s4159…
Two of our scientific leaders will be at #ASGCT2024 next week to present their latest work.
Mark Landon will present findings/data on #AB2100 , our #celltherapy being studied as a potential treatment for #kidneycancer in a phase 1/2 trial. The investigative medicine's unique
